Objective: The aim of this pilot investigation was to show the evidence of the prophylactic immunostimulating effectiveness caused by propolis. The immune response was determined by the measurement of the cytokine level in vivo and ex vivo (TNF-α, IL-6, IL-8). Study Design:In an open prospective monocentric study, test persons received Propolis XNP. Patients: 10 healthy test persons aged between 18 and 45 years, with normal weight and of either sex. Interventions:Probands received over 13 days 500 mg Propolis XNP (2 capsules) for peroral application in the morning. Main Outcome Measures: Significant changes of the investigated cytokine secretion capacity during and after the treatment of propolis compared to the situation without medication. Results:Although the cytokine plasma levels did not significantly change during the study, propolis led to a significant increase of both the spontaneous (TNF-α, p < 0.05; IL-6, p < 0.01; IL-8, p < 0.02; IL-1β, not detectable) and LPS(lipopolysaccaride)-induced (TNF-α, p < 0.001; IL-6, p < 0.02; IL-8, p < 0.0005; IL-1β, p < 0.05) cytokine secretion capacity following short-term ex vivo culture of peripheral blood leukocytes. Whereas the IL-6 secretion capacity further increased during the 13-day application, the IL-8 and TNF-α secretion reached a plateau after day 4 and the TNF-α secretion even decreased, but the level at day 13 was still significantly higher than at day 0. Conclusion: As the cytokine secretion capacity but not the cytokine plasma levels increased significantly during therapy, the prophylactic application of propolis led to a time dependent enhanced immune reactivity without undesired side effects.
Copyright © 1999 S. Karger GmbH, Freiburg
Offizielles Organ der Schweizerischen Medizinischen Gesellschaft für Phytotherapie, European Society for Classical Natural Medicine
Vol. 6, No. 5, Year 1999 (Cover Date: October 1999)
Journal Editor: M. Bühring, München, Germany, K. Linde, München, Germany, W. Marktl, Wien Austria, D. Melchart, München, Germany, K.L. Resch, Bad Elster, Germany, R. Saller, Zürich, Switzerland, M. Ullmann, München, Germany
ISSN: 1021–7096 (print), 1421–9999 (Online)
For additional information: http://www.karger.com/journals/fkm
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.